COSCIENS Biopharma Inc.
CSCIF
$2.08
-$0.08-3.92%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -46.05% | 83.27% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -46.05% | 83.27% | |||
| Cost of Revenue | -47.15% | 67.93% | |||
| Gross Profit | -44.05% | 119.86% | |||
| SG&A Expenses | -20.33% | -9.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -30.11% | -0.29% | |||
| Operating Income | 11.47% | 34.95% | |||
| Income Before Tax | 32.63% | 26.13% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 32.65% | 26.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 32.65% | 26.10% | |||
| EBIT | 11.47% | 34.95% | |||
| EBITDA | 13.07% | 37.24% | |||
| EPS Basic | 32.70% | 26.81% | |||
| Normalized Basic EPS | 41.56% | 26.83% | |||
| EPS Diluted | 32.70% | 26.81% | |||
| Normalized Diluted EPS | 41.56% | 26.83% | |||
| Average Basic Shares Outstanding | 0.08% | 0.96% | |||
| Average Diluted Shares Outstanding | 0.08% | 0.96% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||